Teva Pharmaceutical Industries Ltd
tevapharm.comWhat Do They Do?
Develops, manufactures and sells generic medicines, biosimilars and other medicines to pharmacies, wholesalers and healthcare providers worldwide.
10-K for FY2025, filed Feb 3, 2026We develop, manufacture and sell generic medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants…View ↗
Our innovative medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and…View ↗
We are one of the leading generic pharmaceutical companies in the United States. We market more than 350 generic prescription products in…View ↗
Who Are Their Customers?
Most U.S. generic sales go to retail drug chains, mail-order distributors and wholesalers. Anda distributes products to independent pharmacies, pharmacy chains, hospitals and physician offices; Teva also sells through retail and institutional channels in international markets.
10-K for FY2025, filed Feb 3, 2026We are one of the leading generic pharmaceutical companies in the United States. We market more than 350 generic prescription products in…View ↗
Anda, our distribution business in the United States, distributes generic, biosimilar and innovative medicines, and OTC pharmaceutical…View ↗
The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 29, 2026
−$576MView ↗
- ▼ Now a loss
- vs $282M in Q2 FY2025
10-Q for Q2 FY2026, filed Jul 29, 2026
Open tableView ↗
-
Apr 29, 2026
Agreed to acquire Emalex Biosciences
Sources
8-K, filed Apr 29, 2026
In addition, on April 29, 2026, the Company issued a press release announcing that it has entered into a definitive agreement to acquire…View ↗
Japan venture exit
The older report described a Japanese venture with Takeda that handled much of Teva's business in Japan; the latest report says Teva divested the venture, including generic and legacy products.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 3, 2026In Japan, one of our key markets within our International Markets segment, we operate a majority of our business through a business venture…View ↗
Loading...
